# US 2026/0062673 A1 · Cell therapy compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062673 A1
- Document ID: US20260062673A1
- Status: Published application
- Kind: A1
- Application number: 19/261,900
- Filed: 2025-07-07
- Published: 2026-03-05
- Earliest claimed: 2016-08-10
- Assignees: Aurelius Biotherapeutics, LLC
- Applicants: Aurelius Biotherapeutics, LLC
- Inventors: Edmund SULLIVAN; Theresa WESTFALL
- Web page: https://patentgrep.com/patent/US20260062673A1

## CPC

- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4211: {CD19 or B4}
- A61K 40/4221: {CD20}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 40/4234: {Interleukins [IL]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- C12N 5/0636: {T lymphocytes}
- C12Y 305/01001: Asparaginase (3.5.1.1)
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present disclosure provides compositions of immune cells presenting a target molecule or a fragment thereof and provides compositions and methods of producing immune cell therapies with targeted activity against cancer. Methods for conditioning a subject receiving the immune cell therapy of the disclosure are additionally disclosed. The immune cell therapies of the present disclosure can be administered to a subject in need thereof for diseases such as cancer.

## Claims

### Claim at position 1

1-121. (canceled)

### Claim 122

A method of producing an antigen specific cell, the method comprising:
a) exposing tumor cells to a freeze/thaw cycle to generate a tumor cell extract, wherein the freeze/thaw cycle disrupts the tumor cells; and
b) contacting a first cell with an antigen presenting cell in a culture comprising the tumor cell extract.

### Claim 123 (depends on 122)

The method of claim 122, wherein the antigen specific cell is produced from the first cell.

### Claim 124 (depends on 123)

The method of claim 123, wherein the antigen specific cell is a CD20 antigen specific cell.

### Claim 125 (depends on 124)

The method of claim 124, wherein the antigen specific cell is a T cell.

### Claim 126 (depends on 125)

The method of claim 125, wherein the T cell expresses CD5, CD8 or CD4.

### Claim 127 (depends on 125)

The method of claim 125, wherein the T cell is a propagated T cell.

### Claim 128 (depends on 123)

The method of claim 123, wherein the freeze/thaw cycle comprises exposing the tumor cells to about −120° C. for about 5 minutes and thawing the tumor cells to about 37° C.

### Claim 129 (depends on 123)

The method of claim 123, wherein the tumor cells comprise an autologous tumor cell, an allogeneic tumor cell, or a combination thereof.

### Claim 130 (depends on 123)

The method of claim 123, wherein the culture comprises an interleukin.

### Claim 131 (depends on 123)

The method of claim 123, wherein the antigen presenting cell comprises a dendritic cell, a macrophage, a monocyte, or a B cell.

### Claim 132 (depends on 123)

The method of claim 123, wherein the antigen presenting cell presents CD20 or an antigenic fragment thereof.

### Claim 133 (depends on 132)

The method of claim 132, wherein the CD20 is a recombinant CD20.

### Claim 134 (depends on 132)

The method of claim 132, wherein the antigen presenting cell is transfected with a nucleotide sequence encoding the CD20 or the antigenic fragment thereof.

### Claim 135 (depends on 132)

The method of claim 132, wherein the CD20 or the antigenic fragment thereof comprises a feline CD20 or an antigenic fragment thereof or a canine CD20 or an antigenic fragment thereof.

### Claim 136 (depends on 135)

The method of claim 135, wherein the CD20 or the antigenic fragment thereof comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1.

### Claim 137 (depends on 136)

The method of claim 136, wherein the CD20 or the antigenic fragment thereof comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 138 (depends on 135)

The method of claim 135, wherein the CD20 or the antigenic fragment thereof comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3.

### Claim 139 (depends on 138)

The method of claim 138, wherein the CD20 or the antigenic fragment thereof comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 140 (depends on 123)

The method of claim 123, further comprising administering the antigen specific cell to a subject in need thereof.

### Claim 141 (depends on 140)

The method of claim 140, wherein the subject has a cancer.
